The VIOLET study a prospective, observational, multicentric real-world study conducted in the Democratic Republic of Congo (DRC) evaluated the efficacy, safety, and tolerability of vildagliptin, administered either as monotherapy or in fixed-dose combination with metformin, in adult patients with Type 2 Diabetes Mellitus (T2DM). The study conducted among 245 patients aged 18 years and above were enrolled and followed over a 12-week period, with assessments conducted at baseline, 6 weeks, and 12 weeks. Results demonstrated significant improvements in glycaemic control at 12 weeks.
The study demonstrated that vildagliptin, alone or combined with metformin, provides effective glycaemic improvement with a favourable safety profile in real-world clinical practice, supporting its use as a reliable therapeutic option for achieving glycaemic targets in patients with T2DM.
Disclaimer: This synopsis is intended solely for informational and educational use by registered medical professionals. It is a summary of an external study and does not constitute medical advice, diagnosis, or treatment recommendations.